{"id":912,"date":"2018-05-18T07:06:33","date_gmt":"2018-05-18T07:06:33","guid":{"rendered":"http:\/\/demo.ovathemes.com\/eventador\/?page_id=912"},"modified":"2023-09-23T15:15:22","modified_gmt":"2023-09-23T15:15:22","slug":"meeting-overview","status":"publish","type":"page","link":"https:\/\/pcoschallenge.org\/pcos-pfdd\/meeting-overview\/","title":{"rendered":"Meeting Information"},"content":{"rendered":"

[vc_row equal_height=”yes”][vc_column][vc_empty_space height=”10px”][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1683669320374{padding-bottom: 30px !important;}”][vc_column offset=”vc_col-lg-9 vc_col-md-8″][vc_column_text]<\/p>\n

Polycystic Ovary Syndrome
\nExternally-Led Patient-Focused
\nDrug Development Meeting
\nPresented by<\/h3>\n

[\/vc_column_text][vc_single_image source=”external_link” external_img_size=”262×164″ alignment=”center” css=”.vc_custom_1695116338526{padding-top: -20px !important;padding-bottom: 30px !important;}” custom_src=”https:\/\/pcoschallenge.org\/pcos-pfdd\/wp-content\/uploads\/2023\/04\/pcos-logo.webp”]

\n\t\t\t\t<\/p>\n

About the Meeting Organizer<\/h3>\n

The PCOS Externally-Led Patient-Focused Drug-Development Meeting (PCOS EL-PFDD Meeting) was organized by PCOS Challenge: The National Polycystic Ovary Syndrome Association. Serving nearly 60,000 members, PCOS Challenge is the largest PCOS patient advocacy organization globally. PCOS Challenge is the leading organization advancing PCOS health policy at the federal and state level, patient-centered research and patient-focused drug development and treatment efforts. PCOS Challenge provides support to industry partners at every stage of development, from initial discovery and preclinical phases to post-FDA approval and outcome assessment.<\/p>\n

PCOS EL-PFDD Meeting Background<\/h3>\n

Despite affecting up to 15% of women and a $15 billion annual economic burden in the U.S. alone, polycystic ovary syndrome (PCOS) has yet to see any treatments specifically for the disorder approved by the U.S. Food and Drug Administration (FDA). To address this critical gap in care, PCOS Challenge: The National Polycystic Ovary Syndrome Association has organized the PCOS EL-PFDD Meeting as a listening session for the FDA, product developers, clinicians, and academic researchers to hear directly from individuals with PCOS about the health effects and daily impacts of the condition, their treatment goals, and their decision factors when seeking out or selecting a treatment.<\/p>\n

The PCOS EL-PFDD meeting is being conducted as a parallel effort to the FDA\u2019s PFDD initiative<\/a><\/strong> to more systematically gather patients\u2019 perspectives on their conditions and available therapies to treat their conditions. The input from EL-PFDD meetings can inform the FDA\u2019s oversight during drug development and marketing application reviews.<\/p>\n

Who Should Attend the PCOS EL-PFDD meeting?<\/h3>\n

The PCOS EL-PFDD meeting will be attended by PCOS patients, FDA and other regulatory\/federal agency representatives, medical product developers, academic researchers, clinicians and healthcare professionals specializing in PCOS.\n\t\t\t<\/div>[\/vc_column][vc_column offset=”vc_col-lg-3 vc_col-md-4″]

\t\t\t\t\t\t\n\t\t\t\t\t
When<\/h5>\n\t\t\t\t\tFRIDAY, NOVEMBER 3, 2023<\/span>10:00 AM – 2:30 PM EST<\/span>\n\t\t\t\t<\/div>
\t\t\t\t\t\t\n\t\t\t\t\t
Where<\/h5>\n\t\t\t\t\tRIGGS ALUMNI CENTERCOLLEGE PARK,<\/span>MARYLAND<\/span><\/p>\n

\n\t\t\t\t<\/div>Register Now<\/a>[vc_column_text css=”.vc_custom_1695062910620{padding-top: 20px !important;padding-bottom: 20px !important;}”]Attend In-Person or Remotely<\/strong>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]